ARS Pharmaceuticals, Inc.
SPRY
$8.25
-$0.05-0.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.46% | 5,459.66% | 22,367.80% | 971,120.00% | 297,063.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.46% | 5,459.66% | 22,367.80% | 971,120.00% | 297,063.33% |
| Cost of Revenue | 63.47% | 39.02% | 15.95% | 2.76% | 2.45% |
| Gross Profit | -26.12% | 756.38% | 603.70% | 512.75% | 442.34% |
| SG&A Expenses | 221.06% | 378.22% | 288.09% | 142.86% | 50.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.94% | 270.29% | 199.95% | 100.28% | 36.54% |
| Operating Income | -5,720.56% | -50.04% | -4.59% | 56.34% | 95.43% |
| Income Before Tax | -2,168.28% | -62.41% | -6.44% | 69.09% | 115.24% |
| Income Tax Expenses | -127.78% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2,241.76% | -63.00% | -7.08% | 68.51% | 114.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,241.76% | -63.00% | -7.08% | 68.51% | 114.71% |
| EBIT | -5,720.56% | -50.04% | -4.59% | 56.34% | 95.43% |
| EBITDA | -5,828.13% | -48.58% | -3.63% | 56.86% | 95.55% |
| EPS Basic | -2,282.66% | -59.03% | -4.44% | 69.26% | 113.92% |
| Normalized Basic EPS | -1,519.63% | -40.26% | 11.73% | 78.82% | 120.46% |
| EPS Diluted | -13,705.56% | -77.19% | -24.22% | 51.52% | 97.80% |
| Normalized Diluted EPS | -11,135.05% | -59.51% | -9.10% | 59.99% | 102.63% |
| Average Basic Shares Outstanding | 1.68% | 1.59% | 1.51% | 1.62% | 1.81% |
| Average Diluted Shares Outstanding | -3.74% | 7.24% | 7.18% | 7.32% | 7.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |